Fulcrum Therapeutics and Slate Medicines announced a merger to advance next-generation therapeutics and will list on Nasdaq.
3 reports, 3 independent
Updated Aug 18
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Fulcrum Therapeutics and Slate Medicines announced a merger to advance next-generation therapeutics and will list on Nasdaq.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- Ambros Therapeutics and Werewolf Therapeutics agreed to combine in an all-stock transaction and will begin trading on Nasdaq.
- Jazz Pharmaceuticals and RYTHM are competing in the pharmaceutical market and listed on the Nasdaq stock exchange.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- SAB Biotherapeutics, Inc. began trading on the Nasdaq exchange.
- Argenex SE and Capricor Therapeutics were listed on the Nasdaq stock exchange and are competing in the biotech sector.